As­traZeneca earns an­oth­er ap­proval in jam-packed Chi­nese PD-(L)1 mar­ket, this time in late-stage lung can­cer

One of the first en­trants in the PD-(L)1 mar­ket in Chi­na, British drug­mak­er As­traZeneca is now look­ing to ce­ment its ad­van­tage there with an­oth­er ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.